The role of complement in membranous nephropathy

Area of Science:

• Nephrology
• Immunology
• Pathology

Background:

• Membranous nephropathy (MN) is a leading cause of nephrotic syndrome in adults, characterized by immune deposits in the glomerulus.
• Complement activation is implicated in podocyte injury and proteinuria in MN, with C3 and C5b-9 consistently found in deposits.
• Primary MN, often IgG4-predominant, was thought not to activate the classic complement pathway.

Purpose of the Study:

• To investigate the role of complement activation in the pathogenesis of primary membranous nephropathy.
• To explore the significance of M-type phospholipase A2 receptor (PLA2R) as a target antigen in primary MN.
• To understand the mechanism by which anti-PLA2R antibodies contribute to complement-mediated glomerular injury.

Main Methods:

• Analysis of immune deposits in human MN kidney biopsies.
• In vitro studies examining the interaction of IgG4 anti-PLA2R antibodies with complement pathways.
• Review of existing literature on complement activation in experimental and human MN.

Main Results:

• M-type phospholipase A2 receptor (PLA2R) identified as the primary antigen in most cases of primary MN.
• Evidence suggests that IgG4 anti-PLA2R autoantibodies can activate the lectin complement pathway.
• This pathway activation offers a potential mechanism for complement-driven podocyte injury in primary MN.

Conclusions:

• The identification of anti-PLA2R antibodies provides a focus for understanding complement's role in primary MN.
• Targeting complement activation, particularly the lectin pathway, may offer novel therapeutic strategies for MN.
• Further research into complement inhibition could lead to effective treatments to prevent glomerular injury in membranous nephropathy.